Bacteria and immune treatment before surgery for lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether giving a combination of chemotherapy and immunotherapy before surgery can improve outcomes for people with non-small cell lung cancer. Researchers are also studying how the bacteria in your gut (microbiome) affect how well the treatment works. This approach may shrink the tumor and make it easier to remove surgically.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have a new diagnosis of non-small cell lung cancer (NSCLC) that has not spread beyond the chest (stage IIA-IIIB) and does not have certain genetic mutations.
- You must be healthy enough to have surgery to remove the cancer.
- You must not have had any previous cancer treatment (chemotherapy, radiation, or surgery) for this cancer.
- You must not be taking oral steroids or other medications that suppress your immune system.
- You must not have taken antibiotics or probiotics in the past 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at giving immunotherapy before surgery for certain early-stage lung cancers to help shrink the tumor and improve outcomes. It is mainly for people whose lung cancer can be removed by surgery and who don’t have specific gene changes like EGFR or ALK.
This trial studies how gut bacteria (the microbiome) and the body’s immune signs change over time while you receive PD-1–based immunotherapy for advanced, unresectable non–small cell lung cancer. The goal is to learn which immune and microbial patterns might relate to how well treatment works and how patients respond.
This study looks at a treatment plan that uses immunotherapy before and after surgery for non-small cell lung cancer. The goal is to see if this approach helps patients do better and to find out which patients benefit most.
This study looks at how well immunotherapy given before surgery works for non-small cell lung cancer. It aims to help doctors understand real-world outcomes for patients who receive this treatment.
This trial tests whether giving immunotherapy before surgery helps people with lung cancer. It is for patients who have already started this treatment and are otherwise healthy.
This study tests a combination of an immunotherapy drug (sintilimab) and chemotherapy to see if it can shrink advanced lung cancer enough to make surgery possible. The goal is to improve outcomes for people whose cancer is currently too extensive for surgery.
Hear when a new Neoadjuvant Chemoimmunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.